NEONC TECHNOLOGIES HOLDINGS, INC. 8-K

What Happened

• On June 23, 2026, NeOnc Technologies Holdings, Inc. announced (via a press release furnished with its Form 8-K) that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for NEO100. NEO100 is the company’s lead candidate: an intranasally administered formulation of purified perillyl alcohol designed for non‑invasive nose‑to‑brain delivery.

Key Details

• Date of announcement: June 23, 2026.
• Regulator: Department of Health – Abu Dhabi (DOH) granted IND status.
• Product: NEO100 — intranasal purified perillyl alcohol (lead candidate).
• Filing: Press release was furnished as Exhibit 99.1 to the Form 8-K (Regulation FD disclosure, Item 7.01).

Why It Matters

• IND clearance is a regulatory milestone that typically allows a company to proceed with clinical investigations under the local regulator’s oversight; for investors, this represents a formal step toward potential clinical trials in Abu Dhabi for NEO100.
• The filing does not include financial data or changes in management; it is a disclosure of a development milestone that could affect the timing of future clinical activities and related news flow.